JACC:传统中药可能有益于心脏病患者

2017-06-14 佚名 来宝网

根据美国心脏病学杂志日刊(National Journal of the American College of Cardiology)今天发表的最新技术评论文章,中医药可能有效作为传统西医用于心脏病一级和二级预防的补充或替代方法。

根据美国心脏病学杂志日刊(National Journal of the American College of Cardiology)今天发表的最新技术评论文章,中医药可能有效作为传统西医用于心脏病一级和二级预防的补充或替代方法。

心脏病是全世界死亡的首要原因,尽管西医治疗和预防心脏病方面取得进展,但尚未满足的需求仍然存在。因此,中医药越来越被视为对西医的补充,但到目前为止,随机对照试验总体质量差,有缺陷。

西方科学家因为特殊原因经常拒绝中药,配方由几十种具有许多化学分子的成分组成,难以明确治疗机制;中国的药物治疗与西药不同程度的严格审批,以保证疗效和安全性;大多数在中国试验的中药在美国不能使用。

本次研究的研究人员研究了过去十年发表的关于高血压,血脂异常,糖尿病/糖尿病前期,动脉粥样硬化性心脏病和慢性心力衰竭患者随机对照试验的研究,以评估传统治疗的疗效和安全性中药。

总而言之,某些中药显示了对所研究的心血管健康状况的所有益处。例如,研究人员研究了8项针对中医和高血压的随机对照试验。证据表明,天葵,中孚及降压宝等具有抗高血压作用和良好的安全性,是不耐药或西药不足的潜在替代品。然而,这些益处是否转化为长期心血管保护作用必须通过长期试验来确定。

“值得注意的是,应该记住,中医药通常被视为复杂的配方,经常由个体化的执业者进一步操纵,”该评估的资深作者兼山东济南山东齐鲁医院中医药研究所医生说道。 “中药药物的药理作用和一些活性成分的潜在机制已经被阐明,因此,一些药物可能被用作一种辅助预防心血管疾病的替代方法。”


原始出处:

Panpan Hao, Fan Jiang,et al.Traditional Chinese Medicine for Cardiovascular Disease.J. Am. Coll. Cardiol[J].Volume 69, Issue 24, June 2017 DOI: 10.1016/j.jacc.2017.04.041

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853652, encodeId=d4bf185365262, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Oct 29 03:41:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325392, encodeId=dd49132539223, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 16 03:41:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210763, encodeId=bf82210e6392, content=JACC是周刊,不是日刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93fb2041875, createdName=1831e9d9f1m, createdTime=Wed Jun 14 19:04:48 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210678, encodeId=f4f62106e8de, content=好好学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 14 13:48:14 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210657, encodeId=6acc21065ed0, content=看看了解一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jun 14 13:30:48 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-10-29 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853652, encodeId=d4bf185365262, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Oct 29 03:41:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325392, encodeId=dd49132539223, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 16 03:41:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210763, encodeId=bf82210e6392, content=JACC是周刊,不是日刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93fb2041875, createdName=1831e9d9f1m, createdTime=Wed Jun 14 19:04:48 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210678, encodeId=f4f62106e8de, content=好好学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 14 13:48:14 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210657, encodeId=6acc21065ed0, content=看看了解一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jun 14 13:30:48 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853652, encodeId=d4bf185365262, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Oct 29 03:41:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325392, encodeId=dd49132539223, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 16 03:41:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210763, encodeId=bf82210e6392, content=JACC是周刊,不是日刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93fb2041875, createdName=1831e9d9f1m, createdTime=Wed Jun 14 19:04:48 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210678, encodeId=f4f62106e8de, content=好好学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 14 13:48:14 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210657, encodeId=6acc21065ed0, content=看看了解一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jun 14 13:30:48 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 1831e9d9f1m

    JACC是周刊,不是日刊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1853652, encodeId=d4bf185365262, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Oct 29 03:41:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325392, encodeId=dd49132539223, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 16 03:41:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210763, encodeId=bf82210e6392, content=JACC是周刊,不是日刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93fb2041875, createdName=1831e9d9f1m, createdTime=Wed Jun 14 19:04:48 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210678, encodeId=f4f62106e8de, content=好好学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 14 13:48:14 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210657, encodeId=6acc21065ed0, content=看看了解一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jun 14 13:30:48 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 虈亣靌

    好好学习,感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1853652, encodeId=d4bf185365262, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Oct 29 03:41:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325392, encodeId=dd49132539223, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 16 03:41:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210763, encodeId=bf82210e6392, content=JACC是周刊,不是日刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93fb2041875, createdName=1831e9d9f1m, createdTime=Wed Jun 14 19:04:48 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210678, encodeId=f4f62106e8de, content=好好学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 14 13:48:14 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210657, encodeId=6acc21065ed0, content=看看了解一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jun 14 13:30:48 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 xiaotaiyang1

    看看了解一下了

    0

相关资讯

喝中药时,到底能不能喝绿豆汤?

喝中药时,到底能不能喝绿豆汤? 盛夏即将来临,绿豆汤是人们消暑的常见饮品。在民间经常有吃中药的时候,不要喝绿豆汤,其理由是绿豆解药。到底对不对呢?    绿豆性凉,具有清热解毒的功效,它本身就是一味中药。我们知道,中药的组方通常是多味药物组合而成的,很少是单味的,既然绿豆是中药,就存在和其他药物一起合用的可能。既然可以合用,就不存在解药一说了。 

Oncotarget:传统中药卡塞平(KSP)通过激发自噬抑制胃癌的生长

卡塞平(KSP)是中国研究者开发的一种新的中药。进行此研究的目的是探讨KSP是否能够抑制胃癌生长,并探究其可能的疗效机制。

IO泡沫与中药现代化

今年ASCO即将开幕,今天Xconomy发表一篇文章报道了包括罗氏研发高管James Sabry、Ira Mellman,学术界大腕Drew Pardoll、Padmanee Sharma在内多位免疫疗法支持者对目前免疫疗法投资过热的担忧。Sabry说IO早晚会回到现实中,Mellman说往墙上摔面条希望有些能粘上不可持续,Sharma说组合疗法要有根据,不能是因为你同时有甲药和乙药所以就做甲乙组

2016药品检查报告发布,中药和生化药品发现问题较多

5月31日,国家食药监总局发布《2016年度药品检查报告》,报告包括中英文版,阐述了2016年药品检查情况及检查发现的主要问题,分析了各类检查发现的薄弱环节和潜在质量风险。

石菖蒲——治疗中风、湿疹有奇效

石菖蒲舒心气,畅心神,怡心情,益心志,妙药也……故清解药用之,赖以祛痰秽之浊而卫宫城;滋养药用之,藉以宣心思之结而通神明。”——摘自《重庆堂随笔》 文/ 孙洪胜 山东中医药大学附属医院 主任药师导读:端午时节,民间习用菖蒲作剑,用艾叶作虎,并扎悬于门首,用以辟邪。民谚云: “五月五日午,天师骑艾虎,手执菖蒲剑,蛇虫归地府。”菖蒲为多年生水生湿地植物,因其生长的季节和外形被视为可以感百

盘点:中医药的神奇之处

‘望闻问切’能探查病情,几味草药能化作良药,数根银针能消除病痛……中国传统的中医医学在不少外国人眼中是很“玄”的一件事。而中国中医科学院研究员屠呦呦因发明青蒿素获得2015年诺贝尔生理学或医学奖,“飞鱼”菲尔普斯在2016年奥运会上被拍到身上的拔罐痕,“玄”的中医药正受到世界越来越多的关注。这里梅斯小编整理了近期中医药发挥‘神力’的研究进展与大家一同分享。【1】 Oncotarget:传统中药